3-(3-fluorophenyl)-3-phenylpropanamine | 144451-90-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3-fluorophenyl)-3-phenylpropanamine
• 英文别名: 3-(3-Fluorophenyl)-3-phenylpropan-1-amine
• CAS: 144451-90-1
• 化学式: C₁₅H₁₆FN
• 分子量: 229.297
• InChiKey: SLMQEDIDFLTLAB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(3-fluorophenyl)-3-phenylpropanamine 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 2.25h， 生成 N-[N-[3-(3-fluorophenyl)-3-phenylpropyl]-N'-[3-(1H-imidazol-5-yl)propyl]carbamimidoyl]benzamide
  参考文献：
  名称：

  Synthesis and histamine H2 agonistic activity of arpromidine analogues: replacement of the pheniramine-like moiety by non-heterocyclic groups

  摘要：

  Analogues of the potent histamine H-2 agonist arpromidine, characterized by non-heterocyclic groups (phenyl, cyclo-hexyl, alkyl) instead of the pheniramine-like portion, were prepared and tested for their H-2 agonistic and H-1 antagonistic activity in the isolated guinea pig right atrium and ileum, respectively. In the diphenylpropylguanidine series an increase in H-2 agonistic potency resulted from mono- or difluorination at one or both phenyl rings in the meta and/or para position (pD2 less-than-or-equal-to 7.75 vs pD2 = 7.15 for the unsubstituted parent compound). Compounds chlorinated at both phenyl rings were considerably less potent. Highest combined H-2 agonistic/H-1 antagonistic potency was found in the 4-fluorophenyl series. The arpromidine analogue with cyclohexyl and methyl group instead of phenyl and pyridine ring proved to be 30 times more potent than histamine in the atrium. The H-1 antagonistic potency in cyclohexyl compounds was lower than in the diaryl series. Thus, aromatic rings appear not to be required for high H-2 agonistic potency but are useful for combined H-2 agonistic/H-1 antagonistic activity.

  DOI：

  10.1016/0223-5234(92)90145-q
• 作为产物：
  描述：

  methyl 2-cyano-3-(3-fluorophenyl)-2-propenoate 在 sodium hydroxide 、 lithium aluminium tetrahydride 作用下， 以 甲醇 、 苯 为溶剂， 反应 2.5h， 生成 3-(3-fluorophenyl)-3-phenylpropanamine
  参考文献：
  名称：

  Synthesis and histamine H2 agonistic activity of arpromidine analogues: replacement of the pheniramine-like moiety by non-heterocyclic groups

  摘要：

  Analogues of the potent histamine H-2 agonist arpromidine, characterized by non-heterocyclic groups (phenyl, cyclo-hexyl, alkyl) instead of the pheniramine-like portion, were prepared and tested for their H-2 agonistic and H-1 antagonistic activity in the isolated guinea pig right atrium and ileum, respectively. In the diphenylpropylguanidine series an increase in H-2 agonistic potency resulted from mono- or difluorination at one or both phenyl rings in the meta and/or para position (pD2 less-than-or-equal-to 7.75 vs pD2 = 7.15 for the unsubstituted parent compound). Compounds chlorinated at both phenyl rings were considerably less potent. Highest combined H-2 agonistic/H-1 antagonistic potency was found in the 4-fluorophenyl series. The arpromidine analogue with cyclohexyl and methyl group instead of phenyl and pyridine ring proved to be 30 times more potent than histamine in the atrium. The H-1 antagonistic potency in cyclohexyl compounds was lower than in the diaryl series. Thus, aromatic rings appear not to be required for high H-2 agonistic potency but are useful for combined H-2 agonistic/H-1 antagonistic activity.

  DOI：

  10.1016/0223-5234(92)90145-q

文献信息

• Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
  申请人：Mueller L. Alan

  公开号：US20060142594A1

  公开（公告）日：2006-06-29

  Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

  治疗患有神经系统疾病或障碍的患者的方法和组合物，例如中风、头部创伤、脊髓损伤、脊髓缺血、缺血或低氧引起的神经细胞损伤、癫痫、焦虑、由缺血或低氧引起的神经精神或认知功能障碍，例如经常作为体外循环下心脏手术后的后果发生的，或者神经退行性疾病，例如阿尔茨海默病、亨廷顿病、帕金森病或肌萎缩性侧索硬化症（ALS）。
• US6017965A
  申请人：——

  公开号：US6017965A

  公开（公告）日：2000-01-25
• US6211245B1
  申请人：——

  公开号：US6211245B1

  公开（公告）日：2001-04-03
• US6750244B2
  申请人：——

  公开号：US6750244B2

  公开（公告）日：2004-06-15
• US7268166B2
  申请人：——

  公开号：US7268166B2

  公开（公告）日：2007-09-11